,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', 'destiny-breast04']
destiny-breast04: trastuzumab deruxtecan (t-dxd) in patients with her2-low advanced breast cancer: better pfs and os with t-dxd regardless of hormone receptor status! orr 50%, cbr 70% #asco22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni